PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period

September 12, 2005 updated by: National Taiwan University Hospital
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period.

Study Overview

Status

Unknown

Conditions

Detailed Description

Sampling

  1. Age under 3 year-old: a targeted population contains 500 children will be used for sampling of this group. This cohort were firstly enrolled for a trial of oral Rota vaccine since 2004. They will be followed up in the cohort up to 2006. Sixty children will be enrolled in the group younger than 1 year-old (1-2, 2-3 year-old, 20 children will be enrolled in each age group).
  2. Age of 3 to 5 year-old, cases will be enrolled from volunteered students from kindergarden (3-4, 4-5, 5-6 year-old, 20 children will be enrolled in each age group)
  3. Age of 6 to 15 year-old, cases will be enrolled from volunteered students from elementary school and junior high school ( 30 children will be enrolled in each age group). A total of 300 children will be enrolled from children between 6 year-old and 15 year-old.

3. A total of 460 children between the age of 3 month and 15 y/o will be enrolled.

Procedure of PPD test Children who fit the criteria will be given 0.1 ml of PPD (PPD RT23, 2 units) intradermally, in accordance with the guidelines recommended by WHO (17). The tuberculin for the tests is obtained from Denmark and is used throughout the country. PPD indurations will be read 48 to 72 h after administration at 90 degrees from the longest axis of the arm and recorded to the nearest millimeter. Indurations <=5 mm in diameter are classified as negative, those >5 but <=10 mm as doubtful and those >10 mm as positive according to previous consensus (2). All size of indurations will be recorded for further analysis other than arbiturary classification.

Procedure of ELISPOT assay to detect T cells specific for M. tuberculosis antigens 4 ml whole blood is collected in a heparinized tube first and are processed and scored by two scientists who had no access to personal identifiers or TST results within four hours after collection. We amplified the esat-6 gene from genomic DNA isolated from M bovis strain AN5 by PCR, and cloned it into plasmid vector pET21d (Novagen, Madison, WI, USA). Escherichia coli was transformed with this vector. Recombinant ESAT-6 was recovered from transformed E coli and purified by nickel-affinity chromatography. We did ex-vivo interferon-gamma ELISPOT assays, with 300 000 peripheral blood mononuclear cells per well (14,18). We used purified recombinant ESAT-6 and PPD, in addition to negative controls (no added antigen) and positive controls (phytohaemagglutinin). Positive ESAT-6 test wells were defined as containing at least ten spot-forming cells more than, and at least twice as many as, negative control wells-a detection threshold of one per 30 000 peripheral blood mononuclear cells. Assays were done and independently scored by two scientists who were unaware of exposure category and TST results of contacts. ELISPOT assay wells containing more than 300 spot-forming cells cannot be counted accurately because the spots coalesce. 300 cells per well (equivalent to 1000 cells per million peripheral blood mononuclear cells) was therefore taken as the upper limit for accuracy (15).

Exclusion and Follow-up steps Children who are found to have positive PPD test (>10 mm), have a PPD size in the range of 1st 2.5 percentile or having a positive ELISPOT result at the time of enrollment, will be closely followed up for clinical symptoms and signs of TB and necessary diagnostic workup will be done. If LTBI is highly suspected, prophylaxis will be initiated. Closed contact families and care-givers will be asked to take CXR for excluding active pulmonary TB.

Information collection at the enrollment Cross-sectional study of 160 children will be conducted. Children were examined and assessed for general health condition, BCG vaccination record, and BCG scar over L't arm (19). Possible TB exposure including elderly with chronic cough or unexplained prolonged febrile illness in house-hold contact, any contact history with documented open TB will be thoroughly evaluated. Children with suspicious immuno-compromised status, active lung disease or exposure history of TB will be excluded and follow-up will be done.

Biostatistic method Descriptive analysis will be used for size of PPD and result of ELISPOT. P value is calculated with student t test or Chi-square or Fisher exact test for statistic significance (Version 10.0, SPSS, SPSS Inc. Illinois) between different age group. 95%CI will be calculated for the purpose of cut off value of PPD size (except those with unexpected-found TB disease).

Study Type

Observational

Enrollment

460

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Taiwan
      • Taipei, Taiwan, 100
        • Recruiting
        • National Taiwan University Hospital
        • Contact:
        • Principal Investigator:
          • Pei-Chun Chan, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 months to 15 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria: A healthy child with the age between 3 month to 15 year, who has received BCG in the first month of life as schedule, without history of exposure of tuberculosis. -

Exclusion Criteria: Children not received his BCG within one month after birth, immunodeficiency, received steroid or immunosuppresant within 6 weeks, severe infection within 6 weeks, received life vaccine within 6 weeks

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Investigators

  • Study Chair: Li-Ming Huang, MD, PHD, National Taiwan University Hospital, Pediatrics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2005

Study Completion

December 1, 2005

Study Registration Dates

First Submitted

September 12, 2005

First Submitted That Met QC Criteria

September 12, 2005

First Posted (Estimate)

September 15, 2005

Study Record Updates

Last Update Posted (Estimate)

September 15, 2005

Last Update Submitted That Met QC Criteria

September 12, 2005

Last Verified

June 1, 2005

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 940201

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe